A view from the Center

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

Could 2018 be the year of the Medicaid ACO?

by Jeff Burke, Senior Manager Deloitte Consulting LLP and Matt Siegel, Specialist Leader, Deloitte Consulting LLP

A constant among many Medicaid programs is concern over rising costs. This applies to the 32 states that expanded their programs under the Affordable Care Act (ACA), and those that didn’t. In response, a growing number of states are eyeing alternative payment models (APMs), which reward health care providers for the value they offer, rather than the number of tests and services they perform.

Read more

As health systems pursue scale, M&A could get bigger, more complex in 2018 and beyond

by Bryan Martin and Ion Skillrud, Deloitte & Touche LLP

Over the past several years, consolidation among hospitals and health systems has grown. Even more interesting than the number of mergers and acquisitions (M&A) are the sizes of the transactions, which also have increased. In 2018, we expect hospital and health system M&A trends will likely continue and that these transactions will become larger and more complex.

Read more

2018 health plans outlook: More policy uncertainty likely ahead, but larger market shifts and business trends continue to redefine the sector

by Greg Scott, Vice Chairman, US Health Plans Leader, Deloitte LLP

Looking back on health plan sector developments in 2017, much media attention focused on efforts to repeal and replace the Affordable Care Act (ACA). While the continuing ACA political drama is certainly newsworthy, it’s important to stay focused on larger, abiding trends that are reshaping the health plan sector – and the US health care industry overall.

Read more

Embracing ongoing change in hospital quality measurement

by David Betts, Principal, Deloitte Consulting LLP

Winston Churchill is credited with saying that “to improve is to change, [but] to be perfect is to change often.” Organizations that hope to navigate uncertainty in health care might wish that the pace of change would slow – or disappear altogether. Unfortunately, neither of those scenarios is likely. If the last nine months are any indication,

Read more

Can new investors help medtech refill the new product pipeline?

by Pedro Arboleda, Managing Director, Deloitte Monitor

This week, several of my colleagues and I were at AdvaMed’s annual MedTech Conference where we discussed a wide range of topics, including value-based contracting, cybersecurity, and digital health. Yesterday, I led a panel focused on the decline of early-stage investment in medtech, and its impact on startup activity. During the session, we dove into how dwindling investments in those early phases could put future innovation at risk.

Read more